Abstract 55P
Background
Clinical efficacy of CAR-T cells in solid tumors has been limited due to poor expansion and survival. Most CAR constructs provide signal 1 and 2. Current strategies for providing signal 3 mainly rely on constitutive interleukin signaling, while achieving inducible signaling remains a challenging and highly pursued goal in the field. We hypothesized that adding the intracellular domain of the IL-7 cytokine receptor or its activation motifs to induce signal 3 upon antigen recognition would enhance CAR-T cell activation/persistence.
Methods
CCRs were designed by fusing a scFv to the IL-7Rα intracellular domain with the IL-7Rα or CD8 transmembrane domain. We also created second-generation ICOS or CD28-based CARs incorporating IL-7Rα motifs in different conformations. Construct expression and functionality were assessed in vitro and in vivo.
Results
CCRs were efficiently expressed on the T-cell membrane. In single transduction, CCRs failed to induce STAT5 signaling upon antigen recognition unlike a previously described constitutively active IL-7R (C7R). When the extracellular domain of the C7R was replaced by a scFv, STAT5 activation was not complete, suggesting either some steric concerns or that optimization of the CCR extracellular domain may be needed for correct homodimerization. In co-transduction with a CAR, CCRs did not provide a cytotoxic nor a proliferative advantage. Next, we explored the addition of IL-7Rα signaling motifs within a CAR construct. In vitro, we observed differences in terms of expression and cytotoxicity among the different constructs. Using a model of continuous antigen exposure, some IL7R-based constructs revealed enhanced cytotoxicity compared to the control. In vivo, IL7-based CARs behaved similarly to the control CAR, showing no clear advantage in terms of antitumor activity.
Conclusions
By generating and testing several conformations of IL-7R-based CARs and CCRs, we demonstrate that when IL-7Rα signaling domains are included in these receptors they lack signaling upon antigen recognition. Further analysis of CCR homo/heterodimerization with the IL-2Rɣ will be presented. We believe that these findings may shed light on dynamics of cytokine signaling and allow the design of an inducible CCR.
Legal entity responsible for the study
The authors.
Funding
Asociación Española Contra el Cáncer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract